EFL
SPRO icon

ERn Financial LLC’s Spero Therapeutics SPRO Stock Holding History

ERn Financial LLC’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,766
Closed -$19.1K – 176
2023
Q3 		$19.1K Buy
+15,766
New +$21.8K ﹤0.01% 164

Other funds holding SPRO

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ERn Financial LLC's SPRO Position: Q4 2023 in Review

ERn Financial LLC sold out of Spero Therapeutics (SPRO) in Q4 2023, closing a stake of 15,766 shares — an estimated $19.1K sold.

ERn Financial LLC first reported a position in SPRO in Q3 2023 and held it in 1 quarter. The position peaked at $19.1K in Q3 2023. 50 funds tracked by Wall St. Rank hold SPRO as of Q4 2023.

  • ERn Financial LLC reported no remaining Spero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • ERn Financial LLC sold 15,766 Spero Therapeutics shares in Q4 2023, an estimated $19.1K.
  • ERn Financial LLC first reported a position in Spero Therapeutics in Q3 2023 and held it in 1 quarter.
  • ERn Financial LLC's Spero Therapeutics position peaked at $19.1K in Q3 2023.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2023.

Based on ERn Financial LLC's 13F filing for Q4 2023, filed 19 Jan 2024.